Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings NEURONES: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: NEURONES
  • The company's profit outlook over the next few years is a strong asset.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Sales forecast by analysts have been recently revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: NEURONES
  • Most analysts recommend that the stock should be sold or reduced.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Rating Financials

NEURONES SectorFrance

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

NEURONES SectorFrance

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

-
More ratings

Rating Consensus

NEURONES SectorFrance

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

NEURONES SectorFrance

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

NEURONES SectorFrance

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
945M - -
210B
AA
193B
AA
124B
A
-
120B
BBB
-
119B
AAA
78.1B
BB
58.18B
AAA
49.43B
B
-
44.75B
AAA
Average 99.74B
AA
Weighted average by Cap.
AA